Status
Conditions
About
The objective of the study is to evaluate the effects of halogenated gases on sedation and analgesia, to describe the tolerance and to determine the risk factors for failure, in pediatric intensive care patients during prolonged sedation.
This study will be based on the medical records of patients hospitalized between 2015 and 2020.
Full description
Sedation is a major therapeutic element in patients in intensive care under artificial ventilation, in order to allow their comfort and patient-ventilator synchronization. The use of benzodiazepines in combination with opioids is common practice. However, during prolonged sedation, the effects wane, then the doses must be increased, responsible for an increase in the incidence of a significant withdrawal syndrome in the recovery phase, a source of delay in extubation or early reintubation.
The use of halogenated anesthetic gases is now possible in pediatric intensive care in these patients on artificial ventilation.
Their efficacy and tolerance in prolonged use must be evaluated. Their use could improve the sedative effects, reduce the doses of benzodiazepines and opioids used, and reduce unwanted effects in terms of withdrawal syndrome.
The objective of the study is to evaluate the effects of halogenated gases on sedation and analgesia, to describe the tolerance and to determine the risk factors for failure, in pediatric intensive care patients during prolonged sedation.
This study will be based on the medical records of patients hospitalized between 2015 and 2020.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
- Opposition of the holders of parental authority of the minor patient or the adult patient to the use of the data for the study
50 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal